AU2006326890A1 - Pharmaceutical composition for treating haemorrhagic shock and its consecutive symptoms - Google Patents

Pharmaceutical composition for treating haemorrhagic shock and its consecutive symptoms Download PDF

Info

Publication number
AU2006326890A1
AU2006326890A1 AU2006326890A AU2006326890A AU2006326890A1 AU 2006326890 A1 AU2006326890 A1 AU 2006326890A1 AU 2006326890 A AU2006326890 A AU 2006326890A AU 2006326890 A AU2006326890 A AU 2006326890A AU 2006326890 A1 AU2006326890 A1 AU 2006326890A1
Authority
AU
Australia
Prior art keywords
pro
peptide
arg
gly
fibrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006326890A
Other languages
English (en)
Inventor
Rainer Henning
Peter Petzelbauer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fibrex Medical Research and Development GmbH
Original Assignee
Fibrex Medical Research and Development GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrex Medical Research and Development GmbH filed Critical Fibrex Medical Research and Development GmbH
Publication of AU2006326890A1 publication Critical patent/AU2006326890A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2006326890A 2005-12-23 2006-11-10 Pharmaceutical composition for treating haemorrhagic shock and its consecutive symptoms Abandoned AU2006326890A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT0206705A AT502987A1 (de) 2005-12-23 2005-12-23 Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen
ATA2067/2005 2005-12-23
PCT/AT2006/000465 WO2007070899A2 (de) 2005-12-23 2006-11-10 Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen

Publications (1)

Publication Number Publication Date
AU2006326890A1 true AU2006326890A1 (en) 2007-06-28

Family

ID=37846035

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006326890A Abandoned AU2006326890A1 (en) 2005-12-23 2006-11-10 Pharmaceutical composition for treating haemorrhagic shock and its consecutive symptoms

Country Status (14)

Country Link
US (1) US7897574B2 (https=)
EP (2) EP1962887B1 (https=)
JP (1) JP2009520696A (https=)
KR (1) KR20080108221A (https=)
CN (1) CN101365477A (https=)
AT (2) AT502987A1 (https=)
AU (1) AU2006326890A1 (https=)
CA (1) CA2634026A1 (https=)
DE (1) DE502006004619D1 (https=)
ES (1) ES2331970T3 (https=)
IL (1) IL192349A0 (https=)
NO (1) NO20083191L (https=)
RU (1) RU2008130413A (https=)
WO (1) WO2007070899A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2641908A1 (en) * 2006-02-23 2007-08-30 Fibrex Medical Research & Development Gmbh Peptides and peptide derivatives as well as pharmaceutical compositions containing the same
JP2010540892A (ja) * 2007-09-24 2010-12-24 ファイブレックス メディカル リサーチ アンド デベロップメント ゲーエムベーハー 抗炎症活性を有する化合物をスクリーニングする方法
US20130324469A1 (en) * 2010-12-09 2013-12-05 The Brigham And Women's Hospital, Inc. Fibrinogen and kidney damage
TW201718028A (zh) * 2015-10-13 2017-06-01 賽米克Ｉｐ有限責任公司 Ve-鈣黏蛋白結合性生物結合物
JP7506364B2 (ja) * 2019-10-24 2024-06-26 国立大学法人東海国立大学機構 慢性肺疾患／急性呼吸窮迫症候群の治療薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997844A (en) 1991-02-08 1999-12-07 Diatide, Inc. Technetium-99m labeled peptides for imaging
BR0116122A (pt) 2000-12-12 2003-10-14 Fibrex Medical Res & Dev Gmbh Peptìdeos e/ou proteìnas bem como seu uso para preparar uma composição farmacêutica, terapêutica e/ou preventiva
US20080311103A1 (en) * 2004-03-08 2008-12-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Anti-Inflammatory Peptides and Methods of Use Thereof
AT414097B (de) 2004-06-25 2006-09-15 Petzelbauer Peter Dr Pharmazeutische zubereitung zur behandlung von schock
DK1691827T3 (da) * 2004-06-25 2009-12-14 Fibrex Medical Res & Dev Gmbh Anvendelse af peptider, der er afledt fra beta-kæden af det humane fibrinogen, til behandlling af shock

Also Published As

Publication number Publication date
ATE440282T1 (de) 2009-09-15
KR20080108221A (ko) 2008-12-12
NO20083191L (no) 2008-09-16
CN101365477A (zh) 2009-02-11
EP1962887A2 (de) 2008-09-03
EP2110136A2 (de) 2009-10-21
US20090005310A1 (en) 2009-01-01
JP2009520696A (ja) 2009-05-28
EP2110136A3 (de) 2010-01-27
DE502006004619D1 (de) 2009-10-01
RU2008130413A (ru) 2010-01-27
EP1962887B1 (de) 2009-08-19
ES2331970T3 (es) 2010-01-21
WO2007070899A3 (de) 2007-10-04
AT502987A1 (de) 2007-07-15
CA2634026A1 (en) 2007-06-28
US7897574B2 (en) 2011-03-01
WO2007070899A2 (de) 2007-06-28
IL192349A0 (en) 2008-12-29

Similar Documents

Publication Publication Date Title
JP2012126743A (ja) 出血性障害の処置のための第ｉｘａ因子
TW201722463A (zh) 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
AU2005256121B2 (en) Use of peptides derived from the A alpha or B beta chain of human fibrinogen for the treatment of shock
US7897574B2 (en) Pharmaceutical composition for treating haemorrhagic shock and its consecutive symptoms
EP2987498B1 (en) Treatment of bleeding with low half-life fibrinogen
MX2008008324A (en) Pharmaceutical composition for treating haemorrhagic shock and its consecutive symptoms
JP5268638B2 (ja) 新規局所用抗出血剤としての活性型第Ｘ因子（ＦＸａ）の刺激因子
KR20250084963A (ko) 연조직에 투여하기 위한 인자 ix 변이체 폴리펩타이드
KR20190111912A (ko) 출혈의 치료 또는 예방에 사용하기 위한 혈액 응고 인자 대체품
JPH08301786A (ja) 吸収性骨疾患予防・治療剤
US20240199703A1 (en) Procoagulant peptides and use thereof
US7772371B2 (en) Stimulators of Factor X activated (FXa) as new topical antihemorrhagic agents
AT501263B1 (de) Pharmazeutische zubereitung zur behandlung von schock
EP1635861A1 (en) Compositions comprising factor viii and factor ixa for treating haemophilia
HK1119569B (en) Lipidated tissue factor for use as topical antihemorrhagic agent

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application